Refine by
Cancerous Target Equipment & Supplies
138 equipment items found
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG12014/EGI014 Trastuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG1206A Pertuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: Phase ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: New Formulation. Indication: Cancer. Target: HER2. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: EG12021 Bevacizumab Biosimilar. Indication: Cancer. Target: VEGF. Status: ...
Manufactured by:EirGenix, Inc based inNew Taipei City, TAIWAN
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...
by:PharmAI GmbH based inDresden, GERMANY
The technology behind PharmAI’s DiscoveryEngine allows for an unprecedented level of detail in the representation of drug-target complexes. Besides geometric comparison of binding sites based on local alignments, non-covalent interactions were included as they significantly improve the prediction of binding site similarities. Over many years, PharmAI refined and improved this technology and ...
by:Astraveus based inParis, FRANCE
Macrophages are versatile cells. They exhibit abilities to survive solid tumor microenvironment, to trigger inflammation and to absorb and digest debris or infected cells. CAR-Macrophages (CAR-M) are artificially directed against a cancerous target by a chimeric antigen receptor. CAR-M are still in their clinical infancy, however specific abilities of macrophages make them a promising approach to ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Built on the foundation of Specificity Enhanced Bi-specific Antibody (SEBA) molecules the SEBA-ADC have an advanced mechanism of action. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. While HIRE molecules provide cancer cells specific targeting, and ...
Manufactured by:ALL Chemistry Inc. based inMarlton, NEW JERSEY (USA)
TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma ...
Manufactured by:Khloris Biosciences, Inc. based inMountain View, CALIFORNIA (USA)
iPSC vaccination presents a differentiated approach to cancer treatment, targeting a panoply of antigens, leveraging the patient's immune system for optimized antigen presentation, and engaging both cellular and humoral ...
Manufactured by:VECT-HORUS based inMARSEILLE, FRANCE
Vect-Horus has developed its “VECTrans®” breakthrough technology platform with the objective of making the ‘undruggable’ druggable by overcoming challenges of the BBB, and more generally biological barriers. VECTrans® is based on the specific design and optimization of ‘molecular vectors’ that, once conjugated to a payload, enable its delivery to target ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Our first multi-targeted Treatment System is comprised of VOR33-CLL1 multiplex-edited eHSC therapy and VCAR33-CLL1 multi-specific CAR-T therapy. Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using our novel eHSC platform. Our research demonstrates that multiplex genome editing of allogeneic hematopoietic stem cells may represent ...
by:Genmab A/S based inCopenhagen V, DENMARK
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both generated by Genmab. The antibody pair used to ...
Manufactured by:leadXpro AG based inVilligen, SWITZERLAND
Using X-ray structure-based molecular design, leadXpro has discovered, optimised and patented two new series of selective antagonists of the A2B adenosine receptor. ...
Manufactured by:Curasight based inKøbenhavn N, DENMARK
Curasight's uTRACE is a uPAR-PET imaging and diagnostics technology. It is used to find, visualise, and predict whether a cancer is aggressive and if so, how it should be treated. uTRACE has been tested on over 400 patients in several cancer forms and proven to be ...
Manufactured by:Reglagene Holding, Inc. based inTucson, ARIZONA (USA)
RGN3118 is a potent, orally administered, blood-brain barrier penetrant therapy that has been optimized for the treatment of high-grade gliomas, such as glioblastoma as well as brain metastases from breast, lung, and melanoma cancers. ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our product is a new-generation CAP6 that shows great promise as a highly effective treatment for lung cancer (NSCLC). Lung cancer is one of the most widely prevalent cancers, and one of the most difficult to treat. Eighty-one percent of patients treated for lung cancer die within five ...
Manufactured by:SurgiMab based inMontpellier, FRANCE
SGM-201 is a preclinical stage product based on the same technique that targets ovarian cancer. Both allow surgeons to visualize tumors in real-time with a near-infrared camera, helping them to perform more radical cytoreductive surgery, thus automatically improving surgical outcomes. ...
Manufactured by:Curasight based inKøbenhavn N, DENMARK
Curasight's uTREAT is new type of targeted radiation therapy, targeting and irradiating the cancer cells and almost not healthy tissue. By injecting a substance that seeks all cancer cells, including the metastases that are far away from the primary tumour, this offers a personalised and tailored therapy to each ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
nfP2X7 is a tumour-specific form of the P2X7 ligand-gated ion channel, consisting of three identical protein subunits. When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of diverse physiological functions including proliferation and immune cell functions. Under prolonged stimulation, P2X7 can form a membrane pore that’s ...